Mashrin Chowdhury
Urology · Fort Worth, TXNPI 1831430255
Payments from drug & device makers
Across 316 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Coloplast$1K
- Valencia Technologies Corporation$860
- AbbVie$803
- Axonics, Inc.$769
- Astellas Pharma US Inc$677
- plus $3K from 29 others
What the payments were for
- Grants$2352%
- Travel & lodging$2,11321%
- Food & beverage$7,49875%
- Education$2142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 66 | $2,692 |
| Coloplast | 9 | $1,239 |
| Valencia Technologies Corporation | 3 | $860 |
| AbbVie | 33 | $803 |
| Axonics, Inc. | 27 | $769 |
| Astellas Pharma US Inc | 36 | $677 |
| Sumitomo Pharma America, Inc. | 49 | $549 |
| Boston Scientific | 11 | $487 |
| Urovant Sciences Inc | 33 | $299 |
| Kerecis Limited | 2 | $224 |
| Olympus America Inc. | 7 | $174 |
| Caldera Medical, Inc | 4 | $168 |
| Innovation Technologies Inc | 1 | $109 |
| Progenics Pharmaceuticals, Inc. | 5 | $103 |
| Ferring Pharmaceuticals Inc. | 1 | $98 |
| Johnson & Johnson | 2 | $92 |
| Sun Pharmaceutical Industries Inc. | 1 | $76 |
| Blue Earth Diagnostics | 2 | $70 |
| Merck | 1 | $68 |
| Immunitybio, Inc. | 2 | $66 |
| AstraZeneca(2 entities) | 3 | $50 |
| Dendreon Pharmaceuticals LLC | 2 | $48 |
| Mission Pharmacal Company | 3 | $46 |
| Bluewind Medical | 1 | $46 |
| Calyxo, Inc. | 1 | $32 |
| Biotissue Holdings Inc. | 1 | $31 |
| Procept Biorobotics Corporation | 2 | $29 |
| Laborie Medical Technologies Corp. | 1 | $25 |
| Urogen Pharma, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Neotract Inc. | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
| TELA Bio, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$993
- ALTIS$931
- eCoin Device Kit$841
- Kerecis Omega3 Marigen$801
- ALTAVIVA$320
- Axonics$254
- Kerecis Omega3 SurgiClose$200
- Desara$130
- SpaceOAR VUE System - 10mL$129
- GENERAL ERECTILE DYSFUNCTION$121
- Lupron Depot$114
- Irrisept$109
How this compares
$10,061 in reported general payments places this provider in the 70th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 289 | $192,161 |
| MyrbetriqMirabegron | 75 | $48,489 |
| Estradiol | 112 | $7,391 |
| Mirabegron ErMirabegron | 15 | $4,853 |
| Methenamine Hippurate | 110 | $4,643 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 75 | $2,810 |
| Trospium Chloride | 25 | $1,016 |
| Solifenacin Succinate | 15 | $701 |
| Oxybutynin Chloride ErOxybutynin Chloride | 41 | $625 |
| Cephalexin | 43 | $579 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 74 | $268 |
| Ciprofloxacin Hcl | 64 | $257 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 37 | $248 |
| Tamsulosin Hcl | 27 | $237 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $549 | $192,161289 claims |
| Astellas Pharma US IncMyrbetriq | $677 | $48,48975 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 urology providers in Texas.
Other urology in Fort Worth
- Michael ColliniFort Worth$183K
- Zvi SchiffmanHouston$17.8M
- Jose de la CerdaSan Antonio$9M
- Daniel SaltzsteinSan Antonio$5.8M
- Jose KaramHouston$5.7M
- Daniel ZainfeldSan Antonio$4.7M
- Brian MazzarellaLakeway$4.5M
- Andrew von EschenbachMontgomery$3.2M
- Raj SatkunasivamHouston$2.6M
- Alan SkolnickHouston$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.